XNAS
TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitive conditions, including Fragile X syndrome and Multiple Sclerosis, which have progressed through pre-clinical testing.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | — | -1.83 | — | $88,626 | — | +1.72% | +5.75% | — |
| 2026-05-13 | Q1 2026 | — | 0.43 | — | $388,744 | — | +0.18% | -19.30% | -36.49% |
| 2026-03-31 |
| Q4 2025 |
| — |
| -1.16 |
| — |
| $91,728 |
| — |
| +4.72% |
| -2.99% |
| -9.84% |
| 2025-11-14 | Q3 2025 | — | -1.56 | — | $203,371 | — | — | — | — |
Showing last 4 quarters.